tirzepatide and fatty liver in metabolic dysfunction-associated steatotic disease steatohepatitis: a novel star on the horizon? Fatty Liver Treatment BREAKTHROUGH –

Published veterinary research on the peptide contributed to understanding of its mechanisms and safety profile, though this animal data has not been directly replicated in human clinical trials

Important Context These results come from a controlled clinical trial with regular medical supervision 85% of participants completed the 72-week trial Weight reduction was approximately 6 percentage points greater among women than men in both treatment groups Individual results vary based on adherence, diet, exercise, and other factors The trial excluded participants with type 2 diabetes Side Effects and Safety Considerations Like all medications, Tirzepatide can cause side effects

[83] Georgieff MK

GIP receptor antagonism reverses obesity, insulin resistance, and associated metabolic disturbances induced in mice by prolonged consumption of highfat diet

After removing 2,716 duplicate records, 3,825 studies underwent title and abstract screening

GIPR Component Supports investigation of glucose-dependent pancreatic signaling, adipocyte biology and related pathways